Sawai Group Holdings Co., Ltd.

4887.T
Drug Manufacturers - Specialty & Generic
2026/08/21 Updated
Market Cap: $1.2B (¥190.0B)
Stock Price: $10.35 (¥1,645)
Exchange Rate: 1 USD = ¥158.98

Stock Price Chart

2026/08/21 Updated
16.52
PER (Price Earnings Ratio)
vs Industry Avg: +7.0
1.07
PBR (Price to Book Ratio)
vs Industry Avg: -0.2
3.40%
Dividend Yield
vs Industry Avg: +0.45%

Price Trend

2026/08/21 Updated
Short-term
5-Day MA
+1.66%
Near-term
25-Day MA
-0.18%
Mid-term
75-Day MA
-4.75%
Long-term
200-Day MA
-18.09%

Price & Trading Details

2026/08/21 Updated

PRICE

Previous Close ¥1,609
Open ¥1,627
High ¥1,647
Low ¥1,605
Close ¥1,645

TRADING

Volume 612,900
Average Volume 531,257
Turnover ¥10億
Min. Purchase ¥164,500

Analyst Recommendations 9 analysts

Updated 2026/08/01
Strong Buy
2
2
Buy
5
5
Hold
1
1
Sell
1
1
Strong Sell
0
Target Price (Mean)
¥2,294
None
¥3,200
High
¥2,300
Median
¥1,750
Low
-5% vs Current Price
This information is based on market data from third-party data providers and is for reference only. Investment decisions are your own responsibility.

Earnings Calendar

Updated 2026/08/01
AUG
10
2026
Next Earnings Release
Q3 FY2026
EPS Estimate: ¥83.57

Recent Earnings

Date EPS Est. EPS Actual Surprise
2026/05/14 ¥25.64 ¥-2.70 -110.5%
2026/02/12 ¥59.88 ¥42.46 -29.1%
2025/11/13 ¥35.10 ¥8.27 -76.4%
2025/08/12 ¥83.57 ¥42.36 -49.3%

Shareholder Composition

Updated 2026/08/01
7.6%
Insider Holdings
52.4%
Institutional
40.1%
Public Float
107
Institutional Holders
Insider Holdings 7.6%
Institutional 52.4%
Public Float 40.1%

Major Holders

Updated 2026/08/01
Institution Ownership Shares Change
Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.
2.41%
2.8M 0.00%
Artisan Partners Funds Inc.-Artisan International Small-Mid Fund
1.38%
1.6M -6.61%
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
1.28%
1.5M 0.00%
Victory Portfolios-Victory Trivalent International Small-Cap Fund
0.86%
998.2K -0.05%
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
0.85%
984.6K -0.05%
iShares Trust-iShares Core MSCI EAFE ETF
0.67%
768.7K 0.00%

Dividend History

Updated 2026/08/23
-%
Dividend Yield
¥28
Annual Dividend
-48.1%
YoY Growth
31.1%
Payout Ratio
Year Dividend Change
2026 ¥28 -48.1%
2025 ¥54 +13.3%
2024 ¥48 +10.0%
2023 ¥43 0.0%
2022 ¥43 -

Financial Performance

2026/08/23 Updated

Revenue & Profit

Margins

Cash Flow

Financial Health

2022 2023 2024 2025
Income Statement
Revenue ¥193,816M ¥163,702M ¥176,862M ¥189,024M
Gross Profit ¥66,652M ¥50,252M ¥54,319M ¥56,352M
Operating Income -¥35,888M ¥16,054M ¥18,619M ¥20,808M
Pretax Income -¥35,743M ¥16,248M ¥18,820M ¥20,958M
Net Income -¥28,269M ¥12,667M ¥13,695M ¥22,938M
EPS -¥215.18 ¥96.20 ¥103.93 ¥184.45
Operating Margin -18.52% 9.81% 10.53% 11.01%
Balance Sheet
Total Assets ¥349,502M ¥364,165M ¥382,024M ¥354,623M
Total Equity ¥190,067M ¥201,643M ¥212,662M ¥173,854M
Total Liabilities ¥159,435M ¥162,522M ¥169,362M ¥180,769M
Cash ¥47,717M ¥33,076M ¥26,368M ¥38,785M
Interest-bearing Debt ¥66,749M ¥73,132M ¥82,890M ¥91,339M
Equity Ratio 54.38% 55.37% 55.67% 49.03%
D/E Ratio 0.35 0.36 0.39 0.53
Cash Flow
Operating CF ¥34,310M ¥13,026M ¥23,149M ¥27,851M
Investing CF -¥30,395M -¥27,134M -¥23,112M ¥6,480M
Financing CF -¥11,262M -¥1,267M ¥2,363M -¥32,704M
Free CF ¥10,966M -¥14,115M -¥1,500M ¥337M
Efficiency
ROE -14.87% 6.28% 6.44% 13.19%
ROA -8.09% 3.48% 3.58% 6.47%

Latest IR Information

Company Information

English Name Sawai Group Holdings Co., Ltd.
Japanese Name サワイグループホールディングス(株)
Stock Code 4887.T (JPX)
Sector / Industry Healthcare / Drug Manufacturers - Specialty & Generic
Employees 3,630

About

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the manufacture and sale of pharmaceuticals. The company offers generic drugs in various dosage forms for therapeutic areas comprising cardiovascular and antibiotic preparations, central nervous system drugs, other metabolic drugs, digestive tract medicines, blood and body fluid medications, allergy medications, respiratory medicine, vitamin supplements, oncology drugs, chemotherapeutic agents, genitourinary and anal drugs, and others. It sells its generic drugs through distributors, wholesalers, and retailers. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.

Data provided by Yahoo Finance